Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027
Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.
How this was made
The 30-second read
Why it matters
Pivotal Phase 3 success with statistically significant overall survival improvement and a stated FDA engagement and BLA filing window are likely to shift approval-probability expectations and near-to-medium-term valuation for SLS.
Market read
Traders can reprice SLS on the combination of a positive pivotal OS readout and a concrete regulatory timeline, with the next decision point being FDA discussions and subsequent BLA documentation.
What to watch
The article does not quantify magnitude of adverse events beyond 'mild/moderate' injection-site reactions, and it does not specify how BAT was defined or how cross-over was handled, both of which can matter for FDA review.
Background
Sellas is developing Galinpepimut-S (GPS), a WT1-targeted cancer vaccine, as maintenance therapy for AML patients in second or later remission who cannot undergo stem cell transplant.
Ticker impact
Sellas reported Phase 3 Regal pivotal results for Galinpepimut-S in AML, cutting death risk by 41% and planning an FDA BLA filing in 1H 2027.
Likely upward pressure as traders price in accelerated regulatory momentum and improved probability of approval, tempered by remaining clinical and FDA-path uncertainty.
The article discloses primary Phase 3 success metrics (hazard ratio, p-value, OS improvement) and a concrete next catalyst (FDA meeting and BLA filing timing).
Market effects
Strengthens sentiment for AML immunotherapy/vaccine approaches and can lift peer attention to WT1-targeting strategies and maintenance-therapy trial designs.
Primarily US biotech sentiment, with potential spillover to Nasdaq small-cap biotech liquidity and clinical-trial momentum trades.
Limited direct global macro impact, but can influence international biotech investors tracking US FDA accelerated-approval pathways.
Counterpoint
Even with positive Phase 3 OS, accelerated filing strategies can face FDA scrutiny on endpoints, patient selection, and confirmatory requirements, which may cap upside until additional details emerge.
Key entities
- companySellas Life Sciences
Reported pivotal Phase 3 Regal trial results for Galinpepimut-S in AML and outlined FDA accelerated filing preparations for 1H 2027.
- productGalinpepimut-S (GPS)
Experimental cancer vaccine targeting WT1, evaluated as AML maintenance therapy.
- regulatorU.S. Food and Drug Administration (FDA)
Planned engagement to discuss accelerated filing strategy and BLA submission timing.


